Onsdag 6 Maj | 13:13:51 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
2026-05-06 11:29:00

SynAct Pharma announced this morning that the last patient has completed dosing in the phase IIb ADVANCE study, the company's pivotal trial of resomelagon (AP1189) in newly diagnosed rheumatoid arthritis. With dosing now closed across more than 30 sites, attention shifts to the topline readout, which the company continues to expect in June 2026.

Read the full article at biostock.se:

SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden